Dr. Shaoqing Chen, senior vice president of TYK Medicines, was successfully shortlisted for the leading innovative talent (category A) of the “South Taihu Lake Elite Program” in Huzhou City in July this year with the project of “R&D and industrialization of targeted anti-tumor innovative drug TY-2136b”

Dr. Shaoqing Chen, an internationally renowned pharmacologist, received his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 1992. He went to the United States in 1993 and completed postdoctoral research at the University of Pittsburgh School of Medicine and the Scripps Research Institute, the world’s top biomedical research institute. Since 1998, he has successively served as the senior executive in well-known domestic and multinational pharmaceutical companies, such as Versicor Pharmaceuticals, Roche Pharmaceuticals, Pharmaron Inc, and Furen Medicines Group. He has been engaged in new drug research and development for more than 25 years and has rich experience in new drug R&D and project management.

Dr. Shaoqing Chen has deep attainment in international advanced new drug development technologies such as drug design, computer/AI-aided design, AI PROTAC, molecular gels, and peptide drugs, and has rich R&D experience in the research of protein kinases, protein-protein interactions, and other drug targets. He has made outstanding academic achievements in many fields such as anti-tumor, anti-infection and anti-virus, anti-diabetes, autoimmunity, and antibiotics. For example, for the first time in the world, he applied a complex natural product prostaglandin to synthesize a chemical library in homogeneous synthesis, successfully modified the natural product GE2270A by semi-synthesis to develop a new antibiotic, invented a patent for a new antitumor drug that is a PLK1 inhibitor of a horse globule-like kinase and transferred it to Takeda for an upfront transfer fee of 20 million USD, and invented a potent and selective anti-cancer drug CDK1 inhibitor, RO3306, which is widely used in research laboratories as a tool compound for selective CDK1 inhibitors.

Dr. Shaoqing Chen has led, participated in, and presided over dozens of new drug development projects, successfully developed several compounds for clinical research, published 22 academic papers and international conference presentations in top international academic journals, granted more than 20 international and U.S. invention patents for new drug development, and authored a book chapter in Searching for Combinatorial Chemistry in New Drugs.